Zurich Cantonal Bank
FULC icon

Zurich Cantonal Bank’s Fulcrum Therapeutics FULC Stock Holding History

Zurich Cantonal Bank’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.76K Buy
2,392
+1,210
+102% +$7.36K ﹤0.01% 2496
2026
Q1 		$9.07K Buy
+1,182
New +$11K ﹤0.01% 2484
2025
Q1 		– Sell
-3
Closed -$14 – 2644
2024
Q4 		$14 Sell
3
-2,472
-100% -$9.12K ﹤0.01% 2643
2024
Q3 		$8.84K Hold
2,475
– – ﹤0.01% 2620
2024
Q2 		$15.3K Sell
2,475
-7
-0.3% -$53 ﹤0.01% 2601
2024
Q1 		$23.4K Buy
2,482
+459
+23% +$4.1K ﹤0.01% 2618
2023
Q4 		$13.7K Hold
2,023
– – ﹤0.01% 2670
2023
Q3 		$8.98K Sell
2,023
-668
-25% -$2.92K ﹤0.01% 2743
2023
Q2 		$8.88K Sell
2,691
-7,758
-74% -$22.8K ﹤0.01% 2750
2023
Q1 		$29.8K Buy
10,449
+7,794
+294% +$69.8K ﹤0.01% 2702
2022
Q4 		$19.3K Hold
2,655
– – ﹤0.01% 2759
2022
Q3 		$21K Hold
2,655
– – ﹤0.01% 2789
2022
Q2 		$13K Hold
2,655
– – ﹤0.01% 2835
2022
Q1 		$63K Hold
2,655
– – ﹤0.01% 2459
2021
Q4 		$47K Buy
+2,655
New +$52.6K ﹤0.01% 2759

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Zurich Cantonal Bank's FULC Position: Q2 2026 in Review

Zurich Cantonal Bank increased its Fulcrum Therapeutics (FULC) stake by 102% in Q2 2026, buying an estimated $7.36K and bringing the position to 2,392 shares worth $8.76K. The position accounts for ﹤0.01% of the portfolio, ranked #2496.

Zurich Cantonal Bank first reported a position in FULC in Q4 2021 and has held it in 15 quarters since. The position peaked at $63K in Q1 2022. 154 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • Zurich Cantonal Bank held 2,392 shares of Fulcrum Therapeutics worth $8.76K as of Q2 2026.
  • Zurich Cantonal Bank bought 1,210 Fulcrum Therapeutics shares in Q2 2026, an estimated $7.36K.
  • Fulcrum Therapeutics made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q2 2026, its #2496 holding.
  • Zurich Cantonal Bank first reported a position in Fulcrum Therapeutics in Q4 2021 and has held it in 15 quarters since.
  • Zurich Cantonal Bank's Fulcrum Therapeutics position peaked at $63K in Q1 2022.
  • 154 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Zurich Cantonal Bank's 13F filing for Q2 2026, filed 12 Aug 2026.